Ross\Johnson & Associates LLC Alnylam Pharmaceuticals, Inc. Transaction History
Ross\Johnson & Associates LLC
- $5.83 Billion
- Q1 2025
A detailed history of Ross\Johnson & Associates LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ross\Johnson & Associates LLC holds 1 shares of ALNY stock, worth $285. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$285% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
721Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$4.78 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$3.73 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.72 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.04 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.26 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $35.1B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...